Browse IPMK

Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF03770 Inositol polyphosphate kinase
Function

Inositol phosphate kinase with a broad substrate specificity. Has a preference for inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P4).

> Gene Ontology
 
Biological Process GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0006066 alcohol metabolic process
GO:0016331 morphogenesis of embryonic epithelium
GO:0019751 polyol metabolic process
GO:0021915 neural tube development
GO:0032958 inositol phosphate biosynthetic process
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0043647 inositol phosphate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0060562 epithelial tube morphogenesis
GO:0072175 epithelial tube formation
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function GO:0000823 inositol-1,4,5-trisphosphate 6-kinase activity
GO:0000824 inositol tetrakisphosphate 3-kinase activity
GO:0000825 inositol tetrakisphosphate 6-kinase activity
GO:0008440 inositol-1,4,5-trisphosphate 3-kinase activity
GO:0047326 inositol tetrakisphosphate 5-kinase activity
GO:0051765 inositol tetrakisphosphate kinase activity
GO:0051766 inositol trisphosphate kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04070 Phosphatidylinositol signaling system
hsa00562 Inositol phosphate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1483249: Inositol phosphate metabolism
R-HSA-1430728: Metabolism
R-HSA-1855191: Synthesis of IPs in the nucleus
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IPMK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IPMK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IPMK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1290.651
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1650.848
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0950.867
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0730.791
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0410.974
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1180.943
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1520.643
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4410.72
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1890.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5490.464
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8550.447
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.050.48
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IPMK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IPMK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IPMK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IPMK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IPMK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IPMK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IPMK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIPMK
Nameinositol polyphosphate multikinase
Aliases inositol 1,3,4,6-tetrakisphosphate 5-kinase
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IPMK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.